The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Resistance Exercise and Cannabis Use

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03867786
Recruitment Status : Not yet recruiting
First Posted : March 8, 2019
Last Update Posted : January 20, 2023
Sponsor:
Information provided by (Responsible Party):
Gwendolyn Thomas, Penn State University

Tracking Information
First Submitted Date  ICMJE February 11, 2018
First Posted Date  ICMJE March 8, 2019
Last Update Posted Date January 20, 2023
Estimated Study Start Date  ICMJE February 1, 2023
Estimated Primary Completion Date August 31, 2023   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: March 7, 2019)
  • Cannabis Craving [ Time Frame: change from baseline ]
    Craving Marijuana Craving Questionnaire (MCQ) The 45-item MCQ is a multi-dimensional questionnaire that assesses marijuana craving. It is based on the the Cocaine Craving Questionnaire and uses items that touch on four specific constructs characterizing craving for marijuana: (1) compulsivity, an inability to control marijuana use; (2) emotionality, use of marijuana in anticipation of relief from withdrawal or negative mood; (3) expectancy, anticipation of positive outcomes from smoking marijuana; and (4) purposefulness, intention and planning to use marijuana for positive outcomes. Each item is rated on a seven-point Likert-type scale ranging from "strongly agree to strongly disagree"
  • Cannabis Craving [ Time Frame: Change from baseline ]
    Total Ghrelin as measured by 0.5mL plasma
  • Cannibis Consumption [ Time Frame: change from Baseline ]
    endocannabinoid N-arachidonoylethanolamine (AEA)
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE Not Provided
Original Secondary Outcome Measures  ICMJE Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Resistance Exercise and Cannabis Use
Official Title  ICMJE The Acute Effects of Resistance Exercise on Cannabis Use and Craving
Brief Summary Cannabis is the most widely used illicit drug and rates of hazardous use, and cannabis use disorders (CUDs), have continued to rise in recent years. The highest rates of use and CUDs are seen in young adults (20 - 24 years old) with more than 50% of young adults reporting lifetime use of cannabis, 35% report use in the past year, and 20% report use in the past month. Increased exposure produces higher risk for detrimental psychological and behavioral effects of cannabis use. Given this increased prevalence of cannabis use and associated risks, identifying effective behavioral strategies that reduce cannabis craving, negative psychological effects, and alter neurobiological mechanisms underlying problematic cannabis use are an avenue of needed research. Exercise, particularly resistance exercise, is a behavioral intervention with considerable potential as an adjunctive treatment for CUD.
Detailed Description

Cannabis is the most widely used illicit drug and rates of hazardous use, and cannabis use disorders (CUDs), have continued to rise in recent years. The highest rates of use and CUDs are seen in young adults (20 - 24 years old) with more than 50% of young adults reporting lifetime use of cannabis, 35% report use in the past year, and 20% report use in the past month. Increased exposure produces higher risk for detrimental psychological and behavioral effects of cannabis use. Given this increased prevalence of cannabis use and associated risks, identifying effective behavioral strategies that reduce cannabis craving, negative psychological effects, and alter neurobiological mechanisms underlying problematic cannabis use are an avenue of needed research. Exercise, particularly resistance exercise, is a behavioral intervention with considerable potential as an adjunctive treatment for CUD.

The aims of this proposal seek to address these issues by implementing acute resistance exercise protocol in men and women who have cannabis use disorder. This proposal will: 1 examine the effect of an acute resistance exercise protocol on affect, stress, and compulsive urge to use in non-treatment seeking young adults with CUD 2.examine whether an acute resistance exercise session in individuals with CUD is associated with induced alterations in the appetitive/ reward hormone ghrelin These findings will inform the further development for exercise interventions for cannabis use disorder that can be used with the aim of supporting individuals with CUD reduce use and decrease the negative effects of withdrawal.

Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Cannabis Use Disorder
Intervention  ICMJE
  • Behavioral: Exercise
    Participants will complete an acute exercise visit.
  • Behavioral: Video Control
    Participants will complete a video control visit.
Study Arms  ICMJE
  • Experimental: Exercise Condition
    Participants will undergo a 40 minute exercise protocol
    Intervention: Behavioral: Exercise
  • Active Comparator: Video Control Condition
    Participants will view a 40 minute nature video
    Intervention: Behavioral: Video Control
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Not yet recruiting
Estimated Enrollment  ICMJE
 (submitted: March 7, 2019)
40
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE December 1, 2024
Estimated Primary Completion Date August 31, 2023   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Healthy individuals between the ages of 18-30 years who currently meet for a moderate or severe cannabis use disorder according to DSM-5 criteria.
  2. Untrained (no structured exercise program for at least the previous 6 months) as verified by self-report on a physical activity form.
  3. No previous bone or muscle problems or previous injuries that would prevent free movement about the shoulder, hip, knee or ankle, or increase the risk of discomfort or injury during exercise. No ongoing back problems.
  4. No known endocrine disorders (including, but not limited to Hyperthyroidism, Hypothyroidism, Hyperparathyroidism, Cushing's Syndrome, Diabetes mellitus, metabolic syndrome or other inflammatory disorders).
  5. No history of blood clotting disorders.
  6. Able to read English and complete study assessments
  7. Voluntarily provide informed consent and sign the informed consent document.
  8. Able to provide negative toxicology screenings for substances, except for cannabis, at intake.

Exclusion Criteria:

  1. Meet current criteria for a moderate or severe substance use disorder for any other substance besides cannabis
  2. Have any current psychiatric disorders with acute symptoms (i.e., psychosis, suicidal, homicidal, current mania).
  3. Younger or older than the specified age range of 18-30.
  4. Any endocrine, bone, muscle problems, previous injuries, back problems, or blood clotting disorders.
  5. Cardiac and severe respiratory illnesses (i.e. arrhythmias, enlarged heart, COPD) -
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 30 Years   (Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE
Contact: Gwendolyn Thomas, PhD 8148633172 gat112@psu.edu
Listed Location Countries  ICMJE Not Provided
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03867786
Other Study ID Numbers  ICMJE 12345
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: Undecided
Current Responsible Party Gwendolyn Thomas, Penn State University
Original Responsible Party gwthomas, Syracuse University, Assistant Professor, Exercise Science
Current Study Sponsor  ICMJE Penn State University
Original Study Sponsor  ICMJE Syracuse University
Collaborators  ICMJE Not Provided
Investigators  ICMJE Not Provided
PRS Account Penn State University
Verification Date January 2023

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP